Hyaluronic Acid–Quercetin-Conjugated Silver Nanoparticles Deliver Drugs Directly to Tumor Cells

Lautenschläger Underhill^*
*Correspondence: Lautenschläger Underhill, Department of Pharmacy, University of Szeged, 6720 Szeged, Hungary, Email:

Introduction

In the ever-evolving landscape of cancer treatment, precision medicine stands out as a beacon of hope. Targeted drug delivery systems offer the promise of more effective therapies with fewer side effects. In recent years, nanotechnology has emerged as a powerful tool in this pursuit. Among the myriad of nanoparticle formulations, Hyaluronic Acid–Quercetin-Conjugated Silver Nanoparticles (HAQ-AgNPs) have attracted attention for their potential in delivering drugs directly to tumor cells. Hyaluronic Acid (HA) is a natural polysaccharide found abundantly in the human body, especially in connective tissues and skin. It is recognized for its biocompatibility, biodegradability and low immunogenicity. HA has been extensively studied in drug delivery systems due to its ability to bind specifically to CD44 receptors overexpressed on the surface of many cancer cells. This property makes it an excellent targeting ligand for delivering therapeutic payloads precisely to tumor sites [1].

Quercetin, a flavonoid found in various fruits, vegetables and grains, possesses antioxidant, anti-inflammatory and anti-cancer properties. It has garnered interest in cancer therapy due to its ability to induce apoptosis (programmed cell death) in cancer cells while sparing healthy cells. Quercetin also exhibits synergistic effects when combined with chemotherapeutic agents. Silver Nanoparticles (AgNPs) have unique physicochemical properties, including high surface area-to-volume ratio and size-dependent optical and electronic properties. These characteristics make them suitable for various biomedical applications, including drug delivery. Additionally, silver nanoparticles have intrinsic cytotoxic effects against cancer cells, enhancing the therapeutic potential of HAQ-AgNPs. Combining HA, quercetin and silver nanoparticles creates a multifunctional drug delivery system with enhanced tumor-targeting capabilities and therapeutic efficacy. The HA coating facilitates specific binding to CD44 receptors on cancer cells, promoting internalization of the nanoparticles. Meanwhile, quercetin contributes its anticancer properties, aiding in the induction of apoptosis and sensitization of cancer cells to chemotherapy. The incorporation of silver nanoparticles further augments the cytotoxic effects, potentially leading to synergistic anticancer activity [2].

Description

Conventional chemotherapy often results in significant side effects due to the nonspecific distribution of drugs throughout the body. Targeted drug delivery systems, such as HAQ-AgNPs, offer a solution by delivering payloads directly to tumor sites, thereby reducing off-target effects and improving therapeutic outcomes. The CD44 receptor-targeted approach of HA-coated nanoparticles allows for selective accumulation in cancerous tissues, enhancing drug concentration at the site of action. This targeted delivery not only improves the efficacy of chemotherapeutic agents but also reduces their systemic toxicity, leading to fewer adverse effects for patients. Moreover, the synergistic effects of quercetin and silver nanoparticles enhance the therapeutic index of the formulation, potentially overcoming drug resistance mechanisms and improving treatment outcomes [3].

The development of HAQ-AgNPs as a targeted drug delivery system holds great promise in the field of oncology. Further research is needed to optimize the formulation parameters, including nanoparticle size, surface chemistry and drug loading efficiency, to maximize therapeutic efficacy and biocompatibility. Additionally, preclinical studies and clinical trials are essential to evaluate the safety and efficacy of HAQ-AgNPs in cancer treatment. Hyaluronic Acid– Quercetin-Conjugated Silver Nanoparticles represent a novel approach to targeted drug delivery in cancer therapy. By harnessing the unique properties of HA, quercetin and silver nanoparticles, this formulation offers a multifaceted strategy for delivering therapeutics directly to tumor cells while minimizing off-target effects. As research in nanomedicine continues to advance, HAQAgNPs hold the potential to revolutionize cancer treatment by improving patient outcomes and quality of life [4].

Understanding how HAQ-AgNPs interact with tumor cells at a molecular level is crucial for optimizing their therapeutic efficacy. Upon reaching the tumor site, the HA-coated nanoparticles specifically bind to CD44 receptors overexpressed on the surface of cancer cells, facilitating their internalization via receptor-mediated endocytosis. Once inside the cell, the quercetin component induces apoptosis by targeting various signaling pathways involved in cell survival and proliferation. Meanwhile, the silver nanoparticles exert their cytotoxic effects, further enhancing the anticancer activity of the formulation. Cancer cells often develop resistance to chemotherapy, limiting the effectiveness of conventional treatment regimens. HAQ-AgNPs offer a potential solution to this challenge by leveraging multiple mechanisms of action to combat drug resistance. The combination of HA targeting, quercetininduced apoptosis and silver nanoparticle cytotoxicity can overcome common resistance mechanisms, such as drug efflux pumps and anti-apoptotic signaling pathways. Additionally, the multifunctional nature of HAQ-AgNPs allows for the simultaneous delivery of multiple therapeutic agents, potentially circumventing resistance mechanisms that target individual drugs [5].

Conclusion

Assessing the biocompatibility and safety profile of HAQ-AgNPs is paramount for clinical translation. While silver nanoparticles have demonstrated intrinsic cytotoxicity, their incorporation into HAQ-AgNPs may mitigate adverse effects by reducing systemic exposure and enhancing tumor specificity. Preclinical studies evaluating the pharmacokinetics, biodistribution and toxicity of HAQ-AgNPs are essential for determining their safety profile and informing future clinical trials. Additionally, ongoing research into biodegradable nanoparticle formulations and alternative cytotoxic agents may further enhance the biocompatibility of HAQ-AgNPs for clinical use. Hyaluronic Acid–Quercetin-Conjugated Silver Nanoparticles represent a multifaceted approach to targeted drug delivery in cancer therapy. By harnessing the unique properties of HA, quercetin and silver nanoparticles, this innovative formulation offers a promising strategy for overcoming drug resistance, enhancing imaging and diagnosis and advancing personalized medicine in oncology. Continued research and development efforts are needed to further optimize the therapeutic efficacy, biocompatibility and safety of HAQ-AgNPs for clinical applications, ultimately improving outcomes for cancer patients.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Gomes, Helena IO, Catarina SM Martins and João AV Prior. "Silver nanoparticles as carriers of anticancer drugs for efficient target treatment of cancer cells." Nanomater 11 (2021): 964.

Google Scholar, Crossref, Indexed at

2. Mansoori-Kermani, Amirreza, Sadaf Khalighi, Iman Akbarzadeh and Fazeleh Ranjbar Niavol, et al. "Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer." Mater Today Bio 16 (2022): 100349.

Google Scholar, Crossref, Indexed at

3. Bharadwaj, Kaushik Kumar, Bijuli Rabha, Siddhartha Pati and Bhabesh Kumar Choudhury, et al. "Green synthesis of silver nanoparticles using D. malabarica fruit extract and assessments of their antimicrobial, anticancer and catalytic reduction of 4-nitrophenol (4-NP)." Nanomater 11 (2021): 1999.

Google Scholar, Crossref, Indexed at

4. Perugini, Valeria, Ruth Schmid, Ýrr Mørch and Isabelle Texier, et al. "A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers." Drug Deliv Transl Res 12 (2022): 2089-2100.

Google Scholar, Crossref, Indexed at

5. Zou, Yifang, Fang Xiao, Liu Song and Bingxue Sun, et al. "A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer." Int J Pharm 606 (2021): 120888.

Google Scholar, Crossref, Indexed at